In last trading session, Sangamo Therapeutics Inc (NASDAQ:SGMO) saw 262.28 million shares changing hands with its beta currently measuring 1.24. Company’s recent per share price level of $0.56 trading at $0.16 or 39.55% at ring of the bell on the day assigns it a market valuation of $116.21M. That closing price of SGMO’s stock is at a discount of -164.29% from its 52-week high price of $1.48 and is indicating a premium of 48.21% from its 52-week low price of $0.29. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 27.91 million shares which gives us an average trading volume of 2.27 million if we extend that period to 3-months.

For Sangamo Therapeutics Inc (SGMO), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 2.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.

Sangamo Therapeutics Inc (NASDAQ:SGMO) trade information

Upright in the green during last session for gaining 39.55%, in the last five days SGMO remained trading in the green while hitting it’s week-highest on Wednesday, 07/24/24 when the stock touched $0.56 price level, adding 37.78% to its value on the day. Sangamo Therapeutics Inc’s shares saw a change of 3.07% in year-to-date performance and have moved 28.44% in past 5-day. Sangamo Therapeutics Inc (NASDAQ:SGMO) showed a performance of 19.20% in past 30-days. Number of shares sold short was 15.51 million shares which calculate 5.58 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 12 to the stock, which implies a rise of 95.33% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 19. It follows that stock’s current price would drop -792.86% in reaching the projected high whereas dropping to the targeted low would mean a loss of -792.86% for stock’s current value.

Sangamo Therapeutics Inc (SGMO) estimates and forecasts

Statistics highlight that Sangamo Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 23.29% of value to its shares in past 6 months, showing an annual growth rate of 6.78% while that of industry is 15.30. Apart from that, the company came raising its revenue forecast for fiscal year 2024.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -15.96% during past 5 years.

SGMO Dividends

Sangamo Therapeutics Inc is more likely to be releasing its next quarterly report in August and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Sangamo Therapeutics Inc (NASDAQ:SGMO)’s Major holders

Insiders are in possession of 7.73% of company’s total shares while institution are holding 50.81 percent of that, with stock having share float percentage of 55.07%. Investors also watch the number of corporate investors in a company very closely, which is 50.81% institutions for Sangamo Therapeutics Inc that are currently holding shares of the company. WASATCH ADVISORS LP is the top institutional holder at SGMO for having 20.13 million shares of worth $13.49 million. And as of 2024-03-31, it was holding 11.1634 of the company’s outstanding shares.

The second largest institutional holder is ARMISTICE CAPITAL, LLC, which was holding about 16.96 million shares on 2024-03-31. The number of shares represents firm’s hold over 9.4035 of outstanding shares, having a total worth of $11.37 million.